临床医学
臨床醫學
림상의학
CLINICAL MEDICINE
2015年
1期
34-35,36
,共3页
纳洛酮%慢性阻塞性肺疾病%Ⅱ型呼吸衰竭
納洛酮%慢性阻塞性肺疾病%Ⅱ型呼吸衰竭
납락동%만성조새성폐질병%Ⅱ형호흡쇠갈
Naloxone%Chronic obstructive pulmonary disease%Respiratory failure Ⅱ
目的:探讨纳洛酮治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的临床治疗效果。方法选取信阳市第一人民医院2012年3月至2013年8月收治的84例慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者,将其分为两组,对照组42例采用常规对症治疗,观察组42例采用常规对症治疗加纳洛酮,观察两组患者的治疗效果和不良反应情况。结果观察组总有效率为92.9%,高于对照组的71.4%,且观察组的心脏指数、肺动脉压力、血气分析指标变化均明显优于对照组,差异有统计学意义( P<0.05)。结论纳洛酮治疗可提高慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者的治疗效果,且安全可靠,值得临床推广应用。
目的:探討納洛酮治療慢性阻塞性肺疾病閤併Ⅱ型呼吸衰竭的臨床治療效果。方法選取信暘市第一人民醫院2012年3月至2013年8月收治的84例慢性阻塞性肺疾病閤併Ⅱ型呼吸衰竭患者,將其分為兩組,對照組42例採用常規對癥治療,觀察組42例採用常規對癥治療加納洛酮,觀察兩組患者的治療效果和不良反應情況。結果觀察組總有效率為92.9%,高于對照組的71.4%,且觀察組的心髒指數、肺動脈壓力、血氣分析指標變化均明顯優于對照組,差異有統計學意義( P<0.05)。結論納洛酮治療可提高慢性阻塞性肺疾病閤併Ⅱ型呼吸衰竭患者的治療效果,且安全可靠,值得臨床推廣應用。
목적:탐토납락동치료만성조새성폐질병합병Ⅱ형호흡쇠갈적림상치료효과。방법선취신양시제일인민의원2012년3월지2013년8월수치적84례만성조새성폐질병합병Ⅱ형호흡쇠갈환자,장기분위량조,대조조42례채용상규대증치료,관찰조42례채용상규대증치료가납락동,관찰량조환자적치료효과화불량반응정황。결과관찰조총유효솔위92.9%,고우대조조적71.4%,차관찰조적심장지수、폐동맥압력、혈기분석지표변화균명현우우대조조,차이유통계학의의( P<0.05)。결론납락동치료가제고만성조새성폐질병합병Ⅱ형호흡쇠갈환자적치료효과,차안전가고,치득림상추엄응용。
Objective To study the clinical effect of naloxone on chronic obstructive pulmonary disease combined with respir-atory failureⅡ. Methods 84 patients with chronic obstrutive pulmonary disease and respiratory failureⅡin the first people’ s hospital of Xinyang from March 2012 to August 2013 were selected and divided into two groups,42 patients in control group were given conventional treatment,and 42 patients in observation group were treated with conventional treatment and naloxone. The treatment effects and side effects of the patients in the two groups were observed. Results The total effective rate in treat-ment group was 90. 7%,which was higher than that of the control group(71. 4%). The index changes of CI,pulmonary arterial pressure and blood gas analysis of the patients in observation group was obviously superior to that of the control group,and the differences were significant(P<0. 05). Conclusion Naloxone can improve the therapeutic effect of the patients with COPD and respiratory failureⅡ. It is safe,reliable and worthy of clinical popularization.